# Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

> **NCT00728663** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 35 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00728663
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-09
- **Final completion:** 2010-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728663, "Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00728663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*